Tag:
Victrelis
Latest Headlines
Latest Headlines
Merck CEO assures shareholders there is life after death of Singulair patent
With its $5.5 billion seller Singulair going off patent in two months, things will be a little dicey for the next couple of years at Merck.
CDC delivers gift to hep C drugmakers
The recommendation by the CDC that the 70 million U.S. baby boomers all be tested for hepatitis C is a big gift for the newest hep C treatments.
Merck says Victrelis can interfere with HIV meds
Merck ( $MRK ) has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck...
Merck CEO Frazier: "The future of the industry is going to be more partnerships"
Merck ( $MRK ) CEO Kenneth Frazier is deploying his deal team this year with some very specific instructions to step up their game. Speaking to an investor group, the CEO made it clear that the pharma
Hep C smackdown: Vertex at $420M, Merck at $31M
It's convenient for hepatitis C market-watchers that Vertex Pharmaceuticals ($VRTX) and Merck ($MRK) reported their earnings less than 24 hours apart. There's no need to speculate about how the two
Merck: Don't declare a hep C victor yet
Merck ( $MRK ) released its first sales numbers for hepatitis C newbie Victrelis, confirming that rival Vertex Pharmaceuticals ( $VRTX ) is in the lead. Merck's drug brought in $21 million for the
Incivek storms hep C market with $75M launch
There's no doubt that the hepatitis C market was waiting for Incivek. In its first five weeks on the market, the Vertex Pharmaceuticals drug reaped nearly $75 million in sales. That's more than twice
Merck gets Roche to sell HCV drug in EU, elsewhere
The showdown for marketing new oral drugs against hepatitis C is getting hotter. On the heels of gaining EU approval of HCV drug Victrelis (boceprevir), Merck ( $MRK ) has inked a new deal with Swiss
Vertex jumps on early hep C scrip numbers
This could be the drug industry version of Hollywood's first-weekend box office revenues. Vertex Phamaceutical shares spiked on preliminary numbers showing that its new hepatitis C drug is outpacing
NICE hurries to assess new hepatitis C drugs
The UK's cost-effectiveness watchdog is preparing to assess two new-and-highly-anticipated hepatitis C drugs--Merck's Victrelis and Vertex/Johnson & Johnson's Incivek--even before European
